Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain
NCT06239974Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Sep 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Vericiguat oral suspension (Formulation 4) in Coronary Microvascular Dysfunction (CMD) and chest pain (2 arms), sponsored by The University of Hong Kong. Primary endpoints: Stress Myocardial Blood Flow at 36 months and Stress Myocardial Perfusion Reserve at 36 months. Started Sep 2024; status: recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
Coronary Microvascular Dysfunction (CMD)chest pain
Beyond the preview
Go deeper on NCT06239974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239974.